Anheuser-Busch InBev (BUD, Financial), British American Tobacco PLC (BTI, Financial), Sanofi SA (SNY, Financial), and Celgene Corp. (CELG, Financial) have declined to their three-year lows.
Anheuser-Busch InBev (BUD, Financial) declined to $95.06
The prices of Anheuser-Busch InBev (BUD, Financial) shares have declined to $95.06 on May 11, which is only 0.7% above the 3-year low of $94.42.
Anheuser-Busch InBev is a Brazilian-Belgian international beverage and brewing company. The company is the world’s largest brewer and is considered one of the largest fast-moving consumer goods companies in the world. The company was enlarged in October of 2016 when the company purchased SABMiller and concluded a merger. The company is expected to have an estimated global market share of 28%.
Anheuser-Busch InBev has a market cap of $161.08 billion; its shares were traded around $95.06 with a P/E ratio of 23.45 and P/S ratio of 3.36. The trailing 12-month dividend yield of Anheuser-Busch InBev stocks is 4.55%. The forward dividend yield of Anheuser-Busch InBev stocks is 5.20%. Anheuser-Busch InBev had an annual average earnings growth of 8.70% over the past 10 years.
On April 17 Anheuser-Busch InBev launched its U.S. 2025 Sustainability Goals, focusing on four key areas. The key areas include renewable electricity and carbon reduction, water stewardship, smart agriculture, and circular packaging. According to the goals, by 2025 100% of the company’s purchased electricity will come from renewable sources and carbon dioxide produced will be reduced by 25%.
British American Tobacco PLC (BTI, Financial) declined to $51.50
The prices of British American Tobacco PLC (BTI, Financial) shares have declined to $51.50 on May 11, which is only 3.1% above the 3-year low of $49.91.
British American Tobacco PLC is a British international tobacco company that is the largest publicly traded tobacco company in the world. The company has a market leading position in over 50 countries and operations in 180 countries. Some of its largest selling brands are Dunhill, Lucky Strike, Kent, and Pall Mall.
British American Tobacco PLC has a market cap of $121.62 billion; its shares were traded around $51.50 with a P/E ratio of 2.11 and P/S ratio of 3.85. The trailing 12-month dividend yield of British American Tobacco PLC stocks is 3.90%. The forward dividend yield of British American Tobacco PLC stocks is 5.16%. British American Tobacco PLC had an annual average earnings growth of 13.90% over the past 10 years.
On April 6 British American Tobacco PLC announced that it will continue its commitment to launch tobacco heating and vapor products in Turin, Italy. With the launch, Italy will become the company’s first market in the world to offer its consumers both vapor and tobacco heating products.
Sanofi SA (SNY, Financial) declined to $38.38
The prices of Sanofi SA (SNY, Financial) shares have declined to $38.38 on May 11, which is only 4.1% above the 3-year low of $36.81.
Sanofi SA is a French international pharmaceutical company that is the world’s fifth largest by prescription sales. The company focuses on the research, development, manufacturing, and marketing of pharmaceutical drugs that are both prescription and over the counter. The company covers seven major therapeutic areas including cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines.
Sanofi SA has a market cap of $98.33 billion; its shares were traded around $38.38 with a P/E ratio of 9.62 and P/S ratio of 2.25. The trailing 12-month dividend yield of Sanofi SA stocks is 4.87%. The forward dividend yield of Sanofi SA stocks is 4.92%.
On April 30 Sanofi SA announced that the U.S. Food and Drug Administration has accepted priority review of the Biologics License Application for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma who are not candidates for surgery. Cemiplimab is an investigational human monoclonal antibody targeting the checkpoint inhibitor PD-1 and was granted Breakthrough Therapy designation status by the FDA in September of 2017.
Celgene Corp. (CELG, Financial) declined to $84.54
The prices of Celgene Corp. (CELG, Financial) shares have declined to $84.54 on May 11, which is only 4.1% above the 3-year low of $81.05.
Celgene Corp. is an American biotechnology company that researches, develops, and commercializes treatments relating to cancer and inflammatory disorders. The company’s major product is Revlimid, which in combination with dexamethasone treats multiple myeloma in patients. Revlimid is sold through proprietary risk management distribution programs to ensure safe and appropriate use.
Celgene Corp. has a market cap of $61.28 billion; its shares were traded around $84.54 with a P/E ratio of 24.02 and P/S ratio of 4.97. Celgene Corp. had an annual average earnings growth of 21.40% over the past 5 years.
On May 4 Celgene Corp. reported first quarter 2018 operating and financial results. Net product sales were $3.531 billion for the quarter, a 20% increase from the same period of 2017. Total revenue for the quarter was $3.538 billion, a 19% increase compared to $2.962 billion during the first quarter of 2017. Diluted earnings per share were $1.10 for the quarter compared to $1.15 during the first quarter of 2017.
Disclosure: I do not own stock in any of the companies mentioned in the article.
